Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
AbbVie (NYSE:ABBV) agreed to acquire a device manufacturing facility and associated intellectual property from West Pharmaceutical Services (NYSE:WST) in Tempe, Arizona, expanding its drug delivery device manufacturing capacity.
AbbVie plans to hire approximately 200 employees at the site and to invest more than $175 million to acquire, modernize, and integrate the facility into its global network. The deal transfers multiple production lines and 3.5 mL on-body injector technology to support current and next-generation immunology and neuroscience medicines. The transaction is anticipated to close in mid-2026, subject to closing conditions, and is part of AbbVie's broader plan to invest >$10 billion in U.S. capital over the next decade.
West (NYSE: WST) agreed to sell all manufacturing and supply rights for the SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (NYSE: ABBV) for $112.5 million at close, subject to working capital and other adjustments.
The definitive agreement is subject to closing conditions and is expected to close in mid-2026. West will continue commercial supply and execute ongoing project commitments prior to close, which may include milestone-based payments before closing.
SmartDose 3.5mL revenues represented approximately 4% of fiscal 2025 revenue. West said it will provide more details when it issues 2026 guidance on its Q4 2025 earnings call in February. The company will continue development and manufacture of other SmartDose products, including the SmartDose 10mL system.
West Pharmaceutical Services (NYSE: WST) will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:00 am PST in San Francisco.
The presentation will be available via a live webcast accessible in the Investors section of the company website, with a replay available on the website for approximately 90 days after the event.
West (NYSE: WST) declared a regular quarterly dividend of $0.22 per share on its common stock.
The board declared the dividend on December 9, 2025; it is payable on February 4, 2026 to shareholders of record on January 28, 2026.
West Pharmaceutical Services (NYSE: WST) launched the West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide and said the system will be commercially available in January 2026. The system is described as a fully verified, system-level solution for biologics and vaccines that provides a single design verification and characterization package, a single system-level drug master file and regulatory package, and single-source supply options with make-to-stock and make-to-order and low minimum order quantities.
Management positioned the offering as intended to streamline syringe selection, accelerate regulatory submissions, and secure supply chains, while also cautioning that forward-looking statements contain risks and that there is no certainty the product will achieve particular results.
West Pharmaceutical Services (NYSE: WST) will present at four upcoming investor conferences in November–December 2025. Scheduled appearances include a UBS Global Healthcare fireside chat at 9:30 AM ET on Nov 11, 2025 in Palm Beach Gardens, FL; Jefferies Global Healthcare at 10:00 AM GMT on Nov 18, 2025 in London, UK; Stephens Annual Investment Conference at 11:00 AM CT on Nov 20, 2025 in Nashville, TN; and Citi Global Healthcare at 2:30 PM ET on Dec 2, 2025 in Miami, FL.
The company said live webcasts for each event will be available in the Investors section of the company website, and replays will be accessible for approximately 90 days after each event.
West (NYSE: WST) reported Q3 2025 net sales of $804.6M, up 7.7% (organic +5.0%), and diluted EPS of $1.92 (adjusted-diluted EPS $1.96).
Management raised full-year 2025 guidance to $3.060B–$3.070B net sales and adjusted-diluted EPS to $7.06–$7.11. Q4 guidance introduced: net sales $790M–$800M and adjusted-diluted EPS $1.81–$1.86.
Segment highlights: HVP Components +16.3% (48% of sales), HVP Delivery Devices down 15.7% (one-time $19M 2024 incentive), Proprietary Products and Contract Manufacturing both grew. Nine-month cash flow metrics improved with free cash flow $293.9M.
West (NYSE: WST) will release third-quarter 2025 financial results before the market opens on Thursday, October 23, 2025 and will host a conference call the same day at 8:00 a.m. ET.
The event includes a live webcast, a slide presentation posted in the Investors section of the company website on the day of the call, and a replay available for about 90 days. Participants who wish to ask questions must register in advance to receive a dial-in number and unique PIN for question submission.
West Pharmaceutical Services (NYSE:WST), a global leader in injectable drug administration solutions, has announced its participation in three major investor conferences in September 2025:
- Wells Fargo Healthcare Conference - September 3 in Boston (3:00 PM ET)
- Deutsche Bank Healthcare Summit - September 10 in New York City
- Bank of America Global Healthcare Conference - September 24 in London (3:05 PM GMT)
Live webcasts will be available for the Wells Fargo and Bank of America presentations on the company's investor webpage, with replays accessible for 90 days following the events.
West Pharmaceutical Services (NYSE:WST) reported strong Q2 2025 results with net sales of $766.5 million, up 9.2% year-over-year, and organic growth of 6.8%. The company's diluted EPS reached $1.82, compared to $1.51 in the prior year.
The company's performance was driven by solid growth in High-Value Product (HVP) components, particularly in GLP-1 elastomer growth and Annex 1 projects. The Board approved a Q4 2025 dividend of $0.22 per share, payable on November 19, 2025.
Following strong Q2 results, WST raised its full-year 2025 guidance, projecting net sales of $3.040-3.060 billion (up from $2.945-2.975 billion) and adjusted-diluted EPS of $6.65-6.85 (increased from $6.15-6.35).